329 related articles for article (PubMed ID: 26967478)
1. MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.
Vu HL; Rosenbaum S; Capparelli C; Purwin TJ; Davies MA; Berger AC; Aplin AE
J Invest Dermatol; 2016 Feb; 136(2):453-463. PubMed ID: 26967478
[TBL] [Abstract][Full Text] [Related]
2. MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters.
Yakovian O; Sajman J; Arafeh R; Neve-Oz Y; Alon M; Samuels Y; Sherman E
Cancer Res; 2021 Mar; 81(5):1279-1292. PubMed ID: 33355187
[TBL] [Abstract][Full Text] [Related]
3. Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma.
Vu HL; Aplin AE
Mol Cancer Res; 2014 Oct; 12(10):1509-19. PubMed ID: 24962318
[TBL] [Abstract][Full Text] [Related]
4. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
Posch C; Moslehi H; Feeney L; Green GA; Ebaee A; Feichtenschlager V; Chong K; Peng L; Dimon MT; Phillips T; Daud AI; McCalmont TH; LeBoit PE; Ortiz-Urda S
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):4015-20. PubMed ID: 23431193
[TBL] [Abstract][Full Text] [Related]
5. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
[TBL] [Abstract][Full Text] [Related]
6. Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.
Posch C; Cholewa BD; Vujic I; Sanlorenzo M; Ma J; Kim ST; Kleffel S; Schatton T; Rappersberger K; Gutteridge R; Ahmad N; Ortiz/Urda S
J Invest Dermatol; 2015 Oct; 135(10):2475-2483. PubMed ID: 26016894
[TBL] [Abstract][Full Text] [Related]
7. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
Adam C; Fusi L; Weiss N; Goller SG; Meder K; Frings VG; Kneitz H; Goebeler M; Houben R; Schrama D; Schmidt M
J Invest Dermatol; 2020 Dec; 140(12):2455-2465.e10. PubMed ID: 32376279
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.
Garay T; Molnár E; Juhász É; László V; Barbai T; Dobos J; Schelch K; Pirker C; Grusch M; Berger W; Tímár J; Hegedűs B
Pathol Oncol Res; 2015 Sep; 21(4):957-68. PubMed ID: 25749811
[TBL] [Abstract][Full Text] [Related]
9. A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.
Nagler A; Vredevoogd DW; Alon M; Cheng PF; Trabish S; Kalaora S; Arafeh R; Goldin V; Levesque MP; Peeper DS; Samuels Y
Pigment Cell Melanoma Res; 2020 Mar; 33(2):334-344. PubMed ID: 31549767
[TBL] [Abstract][Full Text] [Related]
10. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Nissan MH; Pratilas CA; Jones AM; Ramirez R; Won H; Liu C; Tiwari S; Kong L; Hanrahan AJ; Yao Z; Merghoub T; Ribas A; Chapman PB; Yaeger R; Taylor BS; Schultz N; Berger MF; Rosen N; Solit DB
Cancer Res; 2014 Apr; 74(8):2340-50. PubMed ID: 24576830
[TBL] [Abstract][Full Text] [Related]
11. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.
Algazi AP; Esteve-Puig R; Nosrati A; Hinds B; Hobbs-Muthukumar A; Nandoskar P; Ortiz-Urda S; Chapman PB; Daud A
Pigment Cell Melanoma Res; 2018 Jan; 31(1):110-114. PubMed ID: 28921907
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.
Malka-Mahieu H; Girault I; Rubington M; Leriche M; Welsch C; Kamsu-Kom N; Zhao Q; Desaubry L; Vagner S; Robert C
Cell Cycle; 2016 Sep; 15(18):2405-9. PubMed ID: 27533468
[TBL] [Abstract][Full Text] [Related]
13. The plasma membrane Ca
Hegedũs L; Garay T; Molnár E; Varga K; Bilecz Á; Török S; Padányi R; Pászty K; Wolf M; Grusch M; Kállay E; Döme B; Berger W; Hegedũs B; Enyedi A
Int J Cancer; 2017 Jun; 140(12):2758-2770. PubMed ID: 27813079
[TBL] [Abstract][Full Text] [Related]
14. GAB2 induces tumor angiogenesis in NRAS-driven melanoma.
Yang Y; Wu J; Demir A; Castillo-Martin M; Melamed RD; Zhang G; Fukunaga-Kanabis M; Perez-Lorenzo R; Zheng B; Silvers DN; Brunner G; Wang S; Rabadan R; Cordon-Cardo C; Celebi JT
Oncogene; 2013 Aug; 32(31):3627-37. PubMed ID: 22926523
[TBL] [Abstract][Full Text] [Related]
15. Imaging Mass Spectrometry for the Classification of Melanoma Based on
Casadonte R; Kriegsmann M; Kriegsmann K; Streit H; Meliß RR; Müller CSL; Kriegsmann J
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982192
[TBL] [Abstract][Full Text] [Related]
16. Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.
Posch C; Sanlorenzo M; Vujic I; Oses-Prieto JA; Cholewa BD; Kim ST; Ma J; Lai K; Zekhtser M; Esteve-Puig R; Green G; Chand S; Burlingame AL; Panzer-Grümayer R; Rappersberger K; Ortiz-Urda S
J Invest Dermatol; 2016 Oct; 136(10):2041-2048. PubMed ID: 27251789
[TBL] [Abstract][Full Text] [Related]
17. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F
Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666
[No Abstract] [Full Text] [Related]
18. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
[TBL] [Abstract][Full Text] [Related]
19. A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.
Cai W; Nguyen MQ; Wilski NA; Purwin TJ; Vernon M; Tiago M; Aplin AE
Cancer Res; 2022 Jul; 82(14):2625-2639. PubMed ID: 35657206
[TBL] [Abstract][Full Text] [Related]
20. Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.
Rebecca VW; Alicea GM; Paraiso KH; Lawrence H; Gibney GT; Smalley KS
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1154-8. PubMed ID: 25130256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
